The calibrated automated thrombogram (CAT or CT) is a thrombin generation assay (TGA) and global coagulation assay (GCA) which can be used as a coagulation test to assess thrombotic risk.[1][2] It is the most widely used TGA.[3] The CAT is a semi-automated test performed in a 96-well plate and requires specialized technologists to be performed.[3] As a result, it has seen low implementation in routine laboratories and has been more limited to research settings.[3][4] Lack of standardization with the CAT has also led to difficulties in study-to-study comparisons in research.[3][5] However, efforts have recently been made towards standardization of the assay.[5][6][7][8] An example of a specific commercial CAT is the Thrombinoscope by Thrombinoscope BV (now owned by Diagnostica Stago).[9]
In 2018, a commercial fully-automated TGA system and alternative to the CAT called the ST Genesia debuted.[3] It has been said that this system should allow for more widespread adoption of TGAs in clinical laboratories.[3][12] The ST Genesia system also shows improved reproducibility compared to the CAT.[3]
References
^Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Béguin S (2002). "The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability". Pathophysiol Haemost Thromb. 32 (5–6): 249–53. doi:10.1159/000073575. PMID13679651. S2CID8378673.
^Douxfils J, Morimont L, Delvigne AS, Devel P, Masereel B, Haguet H, Bouvy C, Dogné JM (January 2020). "Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need". Clin Chem Lab Med. 58 (2): 294–305. doi:10.1515/cclm-2019-0471. PMID31444961. S2CID201644826.